Advances in inducing adaptive immunity using cell-based cancer vaccines: clinical applications in pancreatic cancer

The incidence of pancreatic ductal adenocarcinoma(PDA) is on the rise, and the prognosis is extremely poor because PDA is highly aggressive and notoriously difficult to treat. Although gemcitabine- or 5-fluorouracil-based chemotherapy is typically offered as a standard of care, most patients do not...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of gastroenterology : WJG Vol. 22; no. 18; pp. 4446 - 4458
Main Authors Kajihara, Mikio, Takakura, Kazuki, Kanai, Tomoya, Ito, Zensho, Matsumoto, Yoshihiro, Shimodaira, Shigetaka, Okamoto, Masato, Ohkusa, Toshifumi, Koido, Shigeo
Format Journal Article
LanguageEnglish
Published United States Baishideng Publishing Group Inc 14.05.2016
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The incidence of pancreatic ductal adenocarcinoma(PDA) is on the rise, and the prognosis is extremely poor because PDA is highly aggressive and notoriously difficult to treat. Although gemcitabine- or 5-fluorouracil-based chemotherapy is typically offered as a standard of care, most patients do not survive longer than 1 year. Therefore, the development of alternative therapeutic approaches for patients with PDA is imperative. As PDA cells express numerous tumor-associated antigens that are suitable vaccine targets, one promising treatment approach is cancer vaccines. During the last few decades, cell-based cancer vaccines have offered encouraging results in preclinical studies. Cell-based cancer vaccines are mainly generated by presenting whole tumor cells or dendritic cells to cells of the immune system. In particular, several clinical trials have explored cell-based cancer vaccines as a promising therapeutic approach for patients with PDA. Moreover, chemotherapy and cancer vaccines can synergize to result in increased efficacies in patients with PDA. In this review, we will discuss both the effect of cell-based cancer vaccines and advances in terms of future strategies of cancer vaccines for the treatment of PDA patients.
Bibliography:Mikio Kajihara;Kazuki Takakura;Tomoya Kanai;Zensho Ito;Yoshihiro Matsumoto;Shigetaka Shimodaira;Masato Okamoto;Toshifumi Ohkusa;Shigeo Koido;Division of Gastroenterology and Hepatology, Department of Internal Medicine, the Jikei University School of Medicine (Kashiwa Hospital);Cell Processing Center, Shinshu University Hospital;Department of Advanced Immunotherapeutics, Kitasato University School of Pharmacy;Institute of Clinical Medicine and Research, The Jikei University School of Medicine
Correspondence to: Shigeo Koido, MD, Division of Gastroenterology and Hepatology, Department of Internal Medicine, the Jikei University School of Medicine (Kashiwa Hospital), 163-1 Kashiwashita, Kashiwa, Chiba 277-8567, Japan. shigeo_koido@jikei.ac.jp
Author contributions: Kajihara M, Takakura K, Kanai T, Ito Z, Matsumoto Y, Shimodaira S, Okamoto M, Ohkusa T and Koido S designed the manuscript; Koido S wrote the paper; Kajihara M, Takakura K and Koido S contributed equally to this manuscript.
Telephone: +81-4-71641111 Fax: +81-4-71633488
ISSN:1007-9327
2219-2840
DOI:10.3748/wjg.v22.i18.4446